Evidence map›Paper›PMID 36069590›Full record

ArticleMicrobiology spectrum2022

BD MAX Enteric Bacterial, Bacterial Plus, and Virus Panels for Diagnosis of Acute Infectious Gastroenteritis: a Cost-Benefit Analysis.

Josep Ferrer, Estela Giménez, Diego Carretero, Javier Buesa, Francisco Morillas, Rafael Granell, Amadeo Fuenmayor, David Navarro, Eliseo Albert

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Josep FerrerMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Estela GiménezMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Diego CarreteroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Javier BuesaMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.ORCID 0000-0002-3328-3428
Francisco MorillasDepartment of Applied Economics, School of Economics, University of Valenciagrid.5338.d, Valencia, Spain.
Rafael GranellDepartment of Applied Economics, School of Economics, University of Valenciagrid.5338.d, Valencia, Spain.
Amadeo FuenmayorDepartment of Applied Economics, School of Economics, University of Valenciagrid.5338.d, Valencia, Spain.
David NavarroMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
Eliseo AlbertMicrobiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.ORCID 0000-0002-5037-6095
Universitat de València · ESINCLIVA Health Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Economic assessment is required to gauge the value of implementing PCR syndromic platforms in the microbiology laboratory for the diagnosis of community-acquired acute gastroenteritis (AGE) in pediatric and adult in- and outpatients. A cost-benefit analysis was conducted from a health care system perspective using BD MAX Enteric Bacterial, Bacterial Plus, and Virus panels. Two 6-month periods were selected, in which either conventional procedures (in 2017) or BD MAX PCR multiplex panels (in 2018) were used. We retrospectively reviewed medical records of all patients with positive results and a representative sample of negative ones. A Markov model was used to represent transition probabilities between different health care states from time of stool microbiological study until completion of AGE-episode-associated health care. A total of 1,336 medical records were reviewed (829 in 2018 and 507 in 2017), showing overall a significantly higher positivity rate in 2018 than in 2017 (26% versus 6%,

Indexed as

GastroenteritisVirusesAdultBacteriaChildCost-Benefit AnalysisHumansMolecular Diagnostic TechniquesRetrospective Studiesacute gastroenteritis diagnosisBD MAXcost-benefit analysisMarkov modelsyndromic PCR panel

Identifiers

PMID36069590
PMCPMC9603360
OpenAlexW4294916363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.